PPT-IMAGING OF MEDULLARY COMPLICATIONS OF MYELOMA

H Nèji H Abid A Mâalej S Haddar R Akrout M Ezzeddine S Baklouti Z Mnif J Mnif Imaging department Habib Bourguiba Hospital Rheumatology department . UKMF Spring Day. Assessment of disease response, CR and beyond. .. Roger Owen. St James’s Institute of Oncology. Leeds, UK. Myeloma trials: the challenges. What do we need?. Flow . cytometry. in MM.. Glands . Part 3. Adrenal Medulla . The . adrenal medulla accounts for about 10% of the mass . of the . adrenal . gland. Distinct . embryologically. . and physiologically . from . the cortex, although cortical and medullary hormones often act in a complementary . Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. Rochester, Minnesota. Jacksonville, Florida. Multiple . Myeloma. Monitoring and Therapy. Angela Dispenzieri, M.D.. IMF Patient Workshop . November 4, 2014. . Mayo Clinic College of Medicine . Mayo Clinic Comprehensive Cancer Center. Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Copenhagen. , . June 11. th. . 2016. EU Drug Approval and Reimbursement Policy. No standardized. cost-benefit formula exists across the EU. . The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) . Mechanism of dilution and concentration of urine.. dr. Rida Shabbir. DPT IPMR KMU. Index. Definition . Components . Mechanism . Factors . Functions. Definition . A counter current system refers to a system in which the inflow runs counter to, and in close proximity to the out flow for some distance.. Can we do better?. [Hospital name]. [Date]. What is myeloma?. Cancer of plasma cells. Leads to:. Bone infiltration. - fractures (especially vertebral wedge fractures), hypercalcaemia. - pain. . Lymphoid . System. *. Collects excess interstitial . .. *Protects organism against invading pathogens or antigens by producing immune responses. *Includes all cells, tissues and organs that contain lymphocytes . Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. [Hospital]. [date]. Myeloma: Symptoms to diagnosis . Can we do better?.